May 15, 2008
Market Comments Submitted by Nick at Ambitions as a Stock Trader
By admin
Submitted by My Ambitions as a Trader and Investor
Stock Picks and Trade Ideas for Thursday
New Buy Candidates: GMET, ICAD, NCOC (rebuy), WH, XSI
New Short Sale Candidates:
Add To: DGLY, GTE, RAME, TGH, VISN, WHT, YTEC
My Ambitions as a Trader and Investor is not a registered investment advisor. Please read the complete Small Cap Stocks Blog Disclaimer
Visit 1800blogger to see all of our industry leading blogs.
Topics: Uncategorized | No Comments »
May 15, 2008
Market Scan for Small Cap Stocks on May 14, 2008
By admin
Submitted by Ducimus Plinius
Market Scan for small cap stocks
at the close of the markets on May 14, 2008
The table below identifies the stocks returned on my scan of the US markets for small capitalizations stocks likely to display the characteristics of stocks entering Phase II, as described by Stan Weinstein.
Ducimus Plinius is not a registered investment advisor. Please read the complete Small Cap Stocks Blog Disclaimer
Visit 1800blogger to see all of our industry leading blogs.
Topics: Uncategorized | No Comments »
May 15, 2008
GLUU: Guides to 74% 2008 Gross Margins; Looks to iPhone as Possible New Platform
By admin
Submitted By Knobias ClipReport
Trading on Glu Mobile Inc (NasdaqNM: GLUU) was up 6.856% following this morning’s earnings call in which the company reported Q1 revenues of $20.59M, up 31.15% from last year and beating consensus by 7.41%. Q1 EPS was -$.21, down 133.33% from last year and missing consensus by 320.00%. Adjusted Q1 EPS was $.0.00. For Q2, Non-GAAP net loss is expected to be between -$400,000 and breakeven, or between a loss of -$0.01 and -$0.00 per basic share for the 2nd quarter. The Q2-08 earnings forecast is in-line with current consensus estimates.
During yesterday’s conference call, the company raised its full year guidance as result of better than expected results in Q1 due to the extended Hasbro brand, including other businesses involving China and Mig. The company has also made progress on the integration of its Mig acquisition, as well as its more recent purchase of Superscape. Glu Mobile now ranks as the number one provider of games in China and number two in North America.
Despite a weaker than expected opening at the box office for the film adaptation of Speedracer, the company does not believe the potential challenges at the box office will hinder resutls and expects to produce revenues in the Q2 or Q3 timeframe. Said President & CEO Greg Ballard, “Speedracer has a brand of its own. It’s a racing game as well as a movie, so we expect it to do well regardless of box office numbers. We don’t think it will effect the marketing of the actual game.” Going forward, the company has guided to 74% in gross margins for Q2 and believes that those margins should hold for the year as a result of the increased contribution from Mig and a back half release slate.
With the Nintendo DS portable phenomenon occuring in mobile gaming, the company expects the smartphone gaming experience reach the type of experience seen on DS within the year depending on publishers and developers and how much can be done on new platforms. Said Ballard, “A year from now I think people won’t be talking about DS and iPhone experience being much different, just different in terms of the group of people who are playing it. A lot of people aren’t carrying around a DS, but they’re are carrying iPhones. It may prove to be transformative.”
The company’s hestitation in expanding toward DS has been related to the sudden opportunities with other platforms such as the iPhone, Blackerry, Android, Sidekick, etc., which are more closely aligned with Glu Mobile’s expertise. The detriment in expanding too rapidly into PSP and DS is that Glu’s buisiness model is too different, and runs counter to models of physical goods which can have a number of drawbacks. “We like having platforms that make DS and PSP less compelling than it might have been even six months ago,” said Ballard. “There are different competitive advantages on new platforms. Java and others will continue to be as complex, so the titles that will do best on new platforms will emerge from other mobile platforms due to the branding momentum they’ll have there. And most of what we do is making games work in a portable environment.”
Visit 1800blogger to see all of our industry leading blogs.
Topics: Uncategorized | No Comments »
May 14, 2008
Market Scan for Small Cap Stocks on May 13, 2008
By admin
Submitted by Ducimus Plinius
Market Scan for small cap stocks
at the close of the markets on May 13, 2008
The table below identifies the stocks returned on my scan of the US markets for small capitalizations stocks likely to display the characteristics of stocks entering Phase II, as described by Stan Weinstein.
Ducimus Plinius is not a registered investment advisor. Please read the complete Small Cap Stocks Blog Disclaimer
Visit 1800blogger to see all of our industry leading blogs.
Topics: Uncategorized | No Comments »
May 14, 2008
Market Comments Submitted by Nick at Ambitions as a Stock Trader
By admin
Submitted by My Ambitions as a Trader and Investor
Stock Picks and Trade Ideas for Wednesday
New Buy Candidates:
New Short Sale Candidates:
Add To: AVAN
—————————————
Sold for Profit: CSIQ (+73.40%)
Sold for Loss:
Note: I will post any new buys and short sells in the morning.
My Ambitions as a Trader and Investor is not a registered investment advisor. Please read the complete Small Cap Stocks Blog Disclaimer
Visit 1800blogger to see all of our industry leading blogs.
Topics: Uncategorized | No Comments »
May 14, 2008
Knobias Clip Report (05-13-2008)
By admin
Submitted By Knobias ClipReport
CSIQ: Earnings Cause Solar Rally but Quake May Have Impacted Supply
Tuesday’s session saw a perfect storm present itself after oil reversed earlier losses and set another new all time record. Reports indicated that the US Senate defeated a Republican plan to open new domestic areas to oil drilling but the highs saw a pullback after the Senate did approve a plan to stop filling the Strategic Petroleum Stockpile until prices fell below $75 per barrel.
With the price rise in oil, the solar sector would have come into play. But with Canadian Solar Inc. (CSIQ) reporting better than expected earnings, the sector saw a huge rally on the day.
Canadian Solar reported net revenues for the quarter of $171.2 million (including $2.2 million of silicon material sales), compared to net revenues of $17.5 million for the first quarter of 2007 (including $2.8 million of silicon materials sales) and $127.5 million for the fourth quarter of 2007 (including $2.4 million of silicon materials sales). Net income for the quarter was $19.0 million, or $0.61 per diluted share, compared to a net loss of $3.9 million, or $0.14 per diluted share, for the first quarter of 2007 and net income of $5.9 million, or $0.21 per diluted share, for the fourth quarter of 2007. If share-based compensation expenses of $2.2 million were excluded, non-GAAP net income for the quarter would have been $21.2 million, or $0.65 per diluted share.
The significant upside was mainly contributed by three factors — strong pricing, the strong Euro vs. USD, and their internal cost cutting. The Company noted that the large foreign exchange gain was likely a one-time event, but they believed that the other factors would remain positive which would help them maintain a similar level of profitability going forward.
Following the report and the oil rally, shares of Canadian Solar soared over 25% which caused many other names in the sector to see increased buying as well. CSUN (+9%), EMKR (+9%), FSLR (+4.5%), and JASO (+4.3%) were all higher on the day.
But as many already know, China has experienced a devastating earthquake which was centered just north of the Sichuan provincial capital Chengdu in central China, destroying urban areas and mountain villages. In a research note, Caylon Securities felt that the massive quake may have impacted many polysilicon producers. Polysilicon plants in the region, however, did not experience structural damage.
But with the more than 10,000 estimated lost in the tragedy, workers would be lucky to have not experienced a loss in their immediate family and friends. Solar cell makers who may have been impacted from suppliers in this region include Yingli Green Energy Holdings (YGE), Solarfun Power Holdings (SOLF), and possibly Suntech Power Holdings (STP). Shares of YGE were up 3.75%, SOLF was up 6.7%, while STP was up 6%. With more news reports regarding the damage from the Chinese quake, investors would be wise to follow these names for any news of disrupted polysilicon supply.
Visit 1800blogger to see all of our industry leading blogs.
Topics: Uncategorized | No Comments »
May 13, 2008
Market Comments Submitted by Nick at Ambitions as a Stock Trader
By admin
Submitted by My Ambitions as a Trader and Investor
Stock Picks and Trade Ideas for Tuesday
New Buy Candidates: CEGE, FPP, MXB, NNBR, TKLC, VIT
New Short Sale Candidates:
Add To: CLFD, DGLY, GEOI, IPHS, ISYS, MEA, NYNY, OFI, PDO, PPO, SNHY, VISN, VIT (if you already bought)
My Ambitions as a Trader and Investor is not a registered investment advisor. Please read the complete Small Cap Stocks Blog Disclaimer
Visit 1800blogger to see all of our industry leading blogs.
Topics: Uncategorized | No Comments »
May 13, 2008
Market Scan for Small Cap Stocks on May 12, 2008
By admin
Submitted by Ducimus Plinius
Market Scan for small cap stocks
at the close of the markets on May 12, 2008
The table below identifies the stocks returned on my scan of the US markets for small capitalizations stocks likely to display the characteristics of stocks entering Phase II, as described by Stan Weinstein.
Ducimus Plinius is not a registered investment advisor. Please read the complete Small Cap Stocks Blog Disclaimer
Visit 1800blogger to see all of our industry leading blogs.
Topics: Uncategorized | No Comments »
May 13, 2008
Knobias Clip Report (05-12-2008)
By admin
Submitted By Knobias ClipReport
KAMN: Could See Action on Helicopter Shortage
Monday’s session began with a bang for the bulls as bears went into hiding waiting for more ammo in the form of new economic data expected to be reported later in the week. Oil helped the cause with a pullback for the first time in 6 sessions. The price still is extremely elevated heading into the summer driving, but many expected a continued decline with rumors regarding a meeting of US administrators to help the falling greenback.
But even if oil prices drop, the search for it will continue to expand. One area that’s seen growth is off-shore. Evident by the forecasts for Transocean, (RIG), Noble (NE), and Diamond Offshore Drilling (DO) the sector will see higher drilling rates and increased visibility.
National oil companies have been locking in drilling contracts in recent months while most publicly traded oil majors “have been waiting on the sidelines,” Dahlman Rose analyst, Omar Nokta wrote in a client note. “Now, with limited availability and record high leading edge rates, they must combat declining reserves and production to satisfy stakeholder demands.”
The trickledown effect of the increase in off shore drilling is helicopters. With the increased global demand for energy, more helicopter transport will be required with an enhanced standard of safety and productivity.
One name in the sector that might be worth a look is Kaman Corporation (KAMN). The Company conducts its business in the aerospace and industrial distribution markets with Boeing and Sikorsky being its principal customers. According to their latest 10-K, Boeing and Sikorsky compromised 87.8% of total segment sales. Their other customers included Bell Helicopter, Spirit AeroSystems and Shenyang Aircraft Corporation.
The helicopters segment markets its helicopter engineering expertise and performs subcontract work for other manufacturers. It also refurbishes, provides upgrades and supports Kaman SH-2G maritime helicopters operating with foreign militaries as well as K-MAX “aerial truck” helicopters operating with government and commercial customers in several countries. Customers for the SH-2G aircraft include the Egyptian Air Force and the Australian, New Zealand and Polish navies. Operations are primarily conducted at the Bloomfield, Connecticut facility.
Currently, Kaman is trading at an 11.5 P/E ratio and only an 11.2 forward P/E. With a 9.3% estimated growth rate in revenue over the coming year along with a modest 2.2% dividend yield, the name is certainly one to follow over the coming months with the increased demand for all things helicopter. Investors would be wise to watch.
Visit 1800blogger to see all of our industry leading blogs.
Topics: Uncategorized | No Comments »
May 11, 2008
Market Scan for Small Cap Stocks on May 9, 2008
By admin
Submitted by Ducimus Plinius
Market Scan for small cap stocks
at the close of the markets on May 9, 2008
The table below identifies the stocks returned on my scan of the US markets for small capitalizations stocks likely to display the characteristics of stocks entering Phase II, as described by Stan Weinstein.
Ducimus Plinius is not a registered investment advisor. Please read the complete Small Cap Stocks Blog Disclaimer
Visit 1800blogger to see all of our industry leading blogs.
Topics: Uncategorized | No Comments »
May 11, 2008
Knobias Clip Report (05-09-2008)
By admin
Submitted By Knobias ClipReport
CYTX: Management Discusses Increasing Demand for Celution(R) 800 System
Cytori Therapeutics, Inc. (CYTX) reported a first quarter loss today of $8.27 million, or $0.34 a share, from $8.67 million, or $0.43 a share, a year earlier. Analysts had expected a loss of $0.36. The Company reported $153,000 in product revenue, the first time it has recognized Celution System-based revenue.
The Celution(R) 800 System separates and concentrates a patient’s own adult stem and regenerative cells from adipose (fat) tissue to be delivered back to the patient during the same surgical procedure. Adipose tissue is the richest and most accessible known source in the human body of adult stem cells. By comparison, it contains a hundred times more stem cells in the same amount of bone marrow, a commonly-used source for stem cells. While most adult stem cell therapies can take days or weeks of culturing, a meaningful dose can be extracted from adipose tissue in about an hour without the need for further manipulation. This enables “real-time” treatment in the clinical setting, in which a patient can have their own cells harvested and administered without the cells ever leaving the hospital or surgery room.
The system has been introduced in Europe into the plastic and reconstructive surgery market and launched in Japan for cryopreserving a patient’s own stem and regenerative cells. Clinical trials are ongoing or planned in cardiovascular disease, spinal disc degeneration, gastrointestinal disorders, and other unmet medical needs. The Company’s goal for 2008 is to introduce the device to select surgeons and hospitals in Europe and Asia-Pacific to build familiarity with the device ahead of the broader market launch anticipated to follow the completion of the planned clinical studies.
Christopher J. Calhoun, the CEO of Cytori Therapeutics, stated in a conference call today, “Demand for the Celution 800 System has been very encouraging within the European and Asian reconstructive surgery market. In the first quarter, we sold every Celution System and every consumable set that we produced. We also carried a meaningful backlog of orders into the second quarter. Each week, we are seeing more and more physician interest in the technology. Many are contacting us directly and, as a result, increasing cutomer flow through our sales funnel. We remain comfortable with our previous revenue guidance of $10 million to $12 million. We are targeting 75-80 systems in the market by year-end.”
He explained, “We are taking concrete steps to respond to this demand. We are increasing our production capability by adding a second manufacturing shift and outsourcing certain component assemblies. This will allow us to sell more units in Q2 and beyond. We have also expanded our customer sales and training capabilitiesin Asia and Europe. This will allow us to significantly expose more physicians to the technology and solves an important bottleneck in the field. We will also expand our internal sales teams in those regions.”
“We are currently working on several meaningful ways to expand our balance sheet and minimize dilution to our shareholders, while we continue to transform the company to meet the product demand that we see in the market.”
Cytori recently announced that the RESTORE II post-marketing breast reconstruction study has begun. This study has been designed to support reimbursement and market adoption of the Celution 800 System for use in this application. The study will evaluate up to 70 partial mastectomy patients undergoing reconstructive surgery to restore the volume and contour lost from removal of breast tissue associated with tumor removal.
Marc H. Hedrick, M.D., President of Cytori Therapeutics, noted, “Once physicians and nurses have seen what this technology can do, they cant go back to their old ways of doing things. We are seeing physicians working under broad regulatory claims that are taking this technology and applying it to other applications. Doctors often come to us with new ideas and indications. We never cease to be amazed at what doctors can come up with that you didn’t fully anticipate.”
The Company’s StemSource(R) Cell Bank commercialization efforts are ongoing by Green Hospital Supply, Cytori’s exclusive cell bank distribution partner in Japan. Green Hospital Supply, with the support of Cytori, is working closely with a targeted selection of large private and academic hospitals to receive the first StemSource Cell Bank orders in Japan. Additionally, Cytori is working directly with potential StemSource Cell Bank customers in Asia and Europe to expand the market for its fully developed cell banking products and systems.
Dr. Hedrick added, “We are nearing the close on several programs for these banks in Japan, that we will be announcing soon. We will then move into the installation, training and set-up process.”
Mr. Calhoun concluded, “This quarter has been transformational. While we are in the very early days with this technology, and many more challenges remain, the combination of the breadth of opportunity, lack of meaningful competition and quality of our technology and team make the grand and audacious goal of a Celution System in every hospital and major clinic around the world possible.”
Visit 1800blogger to see all of our industry leading blogs.
Topics: Uncategorized | No Comments »
May 9, 2008
Market Comments Submitted by Nick at Ambitions as a Stock Trader
By admin
Submitted by My Ambitions as a Trader and Investor
Stock Picks and Trade Ideas for Friday/Trade Journal
New Buy Candidates:
New Short Sale Candidates: OMG, PDX
Add To: APWR, BPSG, EPM, GENC, IDSA, IPHS, KBX, MRB, VSCI, WEL, WHT
——————–
Sold for Profit:
Sold for Loss: AIXG (-6.0%), BVX (-8.93%), ADEP (-10.70%)
NOTE: I will post the rest of the trade ideas tomorrow. It has been a long and busy day for me and I am a bit tired. I have already finished my research but I would like to see how the markets behave in the morning before I post a exhaustive list of longs.
My Ambitions as a Trader and Investor is not a registered investment advisor. Please read the complete Small Cap Stocks Blog Disclaimer
Visit 1800blogger to see all of our industry leading blogs.
Topics: Uncategorized | 1 Comment »
May 8, 2008
Market Comments Submitted by Nick at Ambitions as a Stock Trader
By admin
Submitted by My Ambitions as a Trader and Investor
Stock Picks and Trade Ideas for Thursday
New Buy Candidates: CGS, CTT, KBX, MEA, NGAS, NYNY, QSC, RDEA, SBLK
New Short Sale Candidates:
Add To: ADEP (if stock reacts favorably), CLFD, EPM, EXXI, GSI, GTE, HDSN, HUSA, JRCC, MRB, WHT
*NGAS and NYNY are risky plays as they have not fully bottomed.
My Ambitions as a Trader and Investor is not a registered investment advisor. Please read the complete Small Cap Stocks Blog Disclaimer
Visit 1800blogger to see all of our industry leading blogs.
Topics: Uncategorized | No Comments »
May 8, 2008
Market Scan for Small Cap Stocks on May 7, 2008
By admin
Submitted by Ducimus Plinius
Market Scan for small cap stocks
at the close of the markets on May 7, 2008
The table below identifies the stocks returned on my scan of the US markets for small capitalizations stocks likely to display the characteristics of stocks entering Phase II, as described by Stan Weinstein.
Ducimus Plinius is not a registered investment advisor. Please read the complete Small Cap Stocks Blog Disclaimer
Visit 1800blogger to see all of our industry leading blogs.
Topics: Uncategorized | No Comments »
May 8, 2008
Knobias Clip Report (05-07-2008)
By admin
Submitted By Knobias ClipReport
ADLS: Management Discusses Q1 Results and Udates Progress with Cethromycin
Advanced Life Sciences Holdings, Inc. (ADLS) announced a first quarter loss $3.6 million, or $0.09 per share, compared to $10.5 million, or $0.37 per share, for the same period last year. Analysts had expected a loss of $0.13 per share.
The Company expects its 2008 cash requirements excluding milestone payments that become due upon NDA filing to fall in the range of $16 million and $17 million. The first quarter cash use of $5.7 million reflects continued NDA submission costs that will curtail substantially in the coming quarters. Accordingly, the Company expects its quarterly cash use to decrease as the Company moves forward with our operations. The cash used will be applied toward remaining cethromycin NDA submission activities, manufacturing costs, medical communication investments, ALS-357 clinical costs, and general operating expenses.
Advanced Life Sciences’ lead candidate, cethromycin, is a novel once-a-day oral antibiotic in late-stage development for the treatment of respiratory tract infections including Community Acquired Pneumonia (CAP).
CAP is the sixth most common cause of death in the United States. Macrolides and penicillins are currently the front-line treatments for respiratory tract infections such as CAP. As macrolide and penicillin resistance grows and has the potential to cause more clinical failures, there is a need for new antibiotics with unique mechanisms of action that can overcome this emerging resistance.
Cethromycin has shown higher in vitro potency and a broader range of activity than macrolides against Gram-positive bacteria associated with respiratory tract infections, and, again in in vitro tests, it appears to be effective against penicillin- and macrolide-resistant bacteria. Cethromycin has a mechanism of action that may slow the onset of future bacterial resistance. In addition to its utility in CAP, cethromycin is also being investigated for the prophylactic treatment of inhalation anthrax post-exposure.
Chairman and CEO of Advanced Life Sciences, Michael T. Flavin, Ph.D., said in a conference call today, “Having confirmed the regulatory plans for cethromycin, we are pushing forward aggressively to achieve our partnering and NDA submission goals. We plan to submit and NDA for cethromycin in CAP in the third quarter of this year. We will seek to have a partner in place at that time.”
He added, “We believe that our cash will be sufficient to allow us to progress into a commercial partnership that will support the ongoing needs of the company.”
John L. Flavin, President and CFO of Advanced Life Sciences, explained, “Our regulatory progress allows us to advance negotiations with potential partners. Partners are encouraged by the clear regulatory pathway for cethromycin. We are confident that we will be successful in forging an attractive partnership. We are also building the franchise through product differentiation and expanding indications. CAP represents only the beginning of the opportunities ahead for cethromycin.”
“We will also seek further funding from the U.S. Department of Defense and U.S. Department of Health and Human Services to develop cethromycin for biodefense indications.”
He added, “As significant shareholders of Advanced Life Sciences, our management team’s interests are aligned with other shareholders. We are taking the right steps to continue to build value in our franchise and company.”
Visit 1800blogger to see all of our industry leading blogs.
Topics: Uncategorized | No Comments »
May 7, 2008
Market Comments Submitted by Nick at Ambitions as a Stock Trader
By admin
Submitted by My Ambitions as a Trader and Investor
Stock Picks and Trade Ideas for Wednesday
New Buy Candidates: APWR (rebuy), AVAN, AXR, BRNC, EXXI, IPHS, ISYS, PZN, RNIN, SCU (on a dip), SNG, SNHY, TELOZ, TGC, VIT (previously mentioned)
New Short Sale Candidates:
Add To: ADEP, AIXG, ASIA, BEXP, BPSG, CSIQ, DMLP, EPM, GTE, HUSA, ICO, MPET, NOG, OTEX, PDO, REXX, SMS, SUTR, TACT, TNS, UFPT, V, VISN, VSCI, WEL, ZEUS
My Ambitions as a Trader and Investor is not a registered investment advisor. Please read the complete Small Cap Stocks Blog Disclaimer
Visit 1800blogger to see all of our industry leading blogs.
Topics: Uncategorized | No Comments »
May 7, 2008
Market Scan for Small Cap Stocks on May 6, 2008
By admin
Submitted by Ducimus Plinius
Market Scan for small cap stocks
at the close of the markets on May 6, 2008
The table below identifies the stocks returned on my scan of the US markets for small capitalizations stocks likely to display the characteristics of stocks entering Phase II, as described by Stan Weinstein.
Ducimus Plinius is not a registered investment advisor. Please read the complete Small Cap Stocks Blog Disclaimer
Visit 1800blogger to see all of our industry leading blogs.
Topics: Uncategorized | No Comments »
May 6, 2008
Knobias Clip Report (05-06-2008)
By admin
Submitted By Knobias ClipReport
Solars Shine as Crude Reaches Another New High
Tuesday’s session saw oil reach another high as the mantra, “another day, another dollar” was heard in sarcastic fashion across the US. With oil breaching new highs, other commodities were also seeing increases on the back of the rise in crude.
With expanding prices in energy, many were rotating their investment dollars back into the solar area as a sympathy play. Solar names were all green with the exception of Emcore Corporation (EMKR).
On Monday, rumors emerged again on LDK Solar Co., Ltd. (LDK) of a potential buyout by Siemens in the mid $40 range. LDK Solar Co., Ltd. is a leading manufacturer of multicrystalline solar wafers, which are the principal raw material used to produce solar cells. LDK sells multicrystalline wafers globally to manufacturers of photovoltaic products, including solar cells and solar modules. In addition, the Company provides wafer processing services to monocrystalline and multicrystalline solar cell and module manufacturers. Shares gained over 5% on heavy volume on the speculation. But after the bell, the Company did report news, though it had nothing to do with a potential takeover.
The Company announced that it signed a five-year contract to supply multicrystalline solar wafers to Germany-based Qimonda AG (Qimonda). Under the terms of the agreement, LDK Solar will deliver approximately 540 MW of multicrystalline solar wafers to Qimonda (or its new joint venture with Centrosolar) over a five-year period commencing in 2009 through 2013. Qimonda will make an advanced payment representing a portion of the contract value to LDK Solar. Qimonda is leveraging its experience with silicon suppliers, as well as the availability of scrap silicon from its DRAM operations, to set up supply contracts with favorable terms. The signed agreement furthermore allows LDK to receive scrap silicon material from Qimonda’s chip production operations. Silicon supply for the initial capacity has been secured with wafers from LDK.
Many who follow the Company will remember that the Company was embroiled in an alleged accounting scandal regarding the capitalizing of supposedly unusable scrap silicon. The accusations have caused the name to experience downward pressure even though the amount disputed in dollars was miniscule in comparison to its overall size.
Even so, the new contract announcement led shares to gains of over 3.5% while memory chip maker, Qimonda (QI) jumped over 18%. With the positive news, shares in all of the solars were ushered higher. JA Solar Holdings (JASO) gained over 10.5% ahead of their first quarter earnings report expected on May 12 (11c estimate vs. 7c last year). Suntech Power Holdings Co. Ltd. (STP) was also higher by over 5.5% following its initiation with a Buy rating by Jesup & Lamont.
With oil hitting new highs, it’s smart to remember that the higher it goes, the closer solar power comes to being cost equivalent. With that in mind, investors would be wise to watch.
Visit 1800blogger to see all of our industry leading blogs.
Topics: Uncategorized | No Comments »
May 6, 2008
Market Comments Submitted by Nick at Ambitions as a Stock Trader
By admin
Submitted by My Ambitions as a Trader and Investor
Stock Picks and Trade Ideas for Tuesday
New Buy Candidates: IDSA, VCI
New Short Sale Candidates:
Add To: CLFD, HUSA, NOG, SUTR
My Ambitions as a Trader and Investor is not a registered investment advisor. Please read the complete Small Cap Stocks Blog Disclaimer
Visit 1800blogger to see all of our industry leading blogs.
Topics: Uncategorized | No Comments »
May 6, 2008
Market Scan for Small Cap Stocks on May 5, 2008
By admin
Submitted by Ducimus Plinius
Market Scan for small cap stocks
at the close of the markets on May 5, 2008
The table below identifies the stocks returned on my scan of the US markets for small capitalizations stocks likely to display the characteristics of stocks entering Phase II, as described by Stan Weinstein.
Ducimus Plinius is not a registered investment advisor. Please read the complete Small Cap Stocks Blog Disclaimer
Visit 1800blogger to see all of our industry leading blogs.
Topics: Uncategorized | No Comments »
May 6, 2008
Knobias Clip Report (05-05-2008)
By admin
Submitted By Knobias ClipReport
SCVM: Expects FDA 510(k) Approval by 2009 in a $500M Market
The older the generation, the more healthcare they require. This fact has been met with more hospitals, additional personnel, and continued development of drugs and devices. But the demand is still outpacing the supply while the population continues to age every day because of more nutritional foods, better technology, and probably more importantly, better healthcare.
Adhering to the supply and demand theory, investors should also cater their portfolios in a similar way. But many will hit a brick wall when trying to decide which pharmaceuticals to invest with the number of candidates involved in the numerous phases for various disorders. Devices are a bit less mysterious but can still create confusion.
One name that should be fairly easy to understand is Scivanta Medical Corp. (SCVM). The Company is a medical product development company which is expecting to lose the developmental stage tag soon.
The Company is managed by David LaVance and Tom Gifford who founded Century Capital Associates. Century Capital is a boutique investment banking firm providing strategic, transaction and financial advisory services to emerging technology companies. The firm specializes in the biotech, pharmaceutical and medical device areas. LaVance serves on the board of directors for Hologic Inc. (HOLX), a medical device company specializing in women’s health care and digital imaging, and Algynomics, Inc., a privately held company pursuing the genetic causes of pain. He also was a former managing director of KPMG Health Ventures and an executive officer of Dornier MedTech, a medical device company focused on lithotripters and other devices. Gifford has served on the board for several development stage life science firms and has extensive experience with startup and middle market life science companies. He also worked at KPMG Health Ventures. Together, they manage Scivanta which owns the rights to develop and distribute the Hickey Cardiac Monitoring System.
The Hickey Cardiac Monitoring System is a minimally invasive cardiac monitoring device which was invented and developed by Dr. Donald Hickey, of the University of Buffalo. For more than a dozen years, Dr. Hickey did research and discovery on the device. The invention sprung from his observations that there was a certain risk in using another medical device, the Swan-Ganz catheter. Scivanta acquired the rights to the Hickey System for a couple hundred thousand dollars, a few milestone payments on approvals, and a 5% royalty fee.
Currently, the Swan-Ganz pulmonary artery catheter is still the standard care for the diagnosis of patients with heart failure, sepsis, congenital heart disease, or burns. Basically, a catheter is inserted through a patient’s artery and snaked into the heart. Often through the internal jugular, subclavian or femoral arteries, the catheter is threaded with the aid of fluoroscopy through the right atrium, right ventricle, and into the pulmonary artery monitoring the performance in each.
The clinical use of the invasive monitoring device is controversial. The risks inherent and costs sometimes outweigh the benefit of its use. But that hasn’t stopped Edwards Life Science (EW) from fully marketing and capitalizing on the device.
Edward’s Critical Care segment includes the FloTrac catheters, Venous Oximetry catheters, Swan-Ganz catheters, Central Venous catheters, and the Vigilance and Vigileo monitors. The company is the largest maker of pulmonary artery catheters. In their latest earnings report, their Critical Care segment grew sales by 17.4% in the first quarter. In their latest 10-K, they reported overall sales of $1.091 billion, of which, the Critical Care segment accounted for $397.8 million. Sales in that segment grew 13.7% from 2006 to 2007.
The growth is somewhat astounding given the life threatening risks (arrhythmias, ruptured arteries, thrombosis, infection, and pneumothorax), the price (Swan-Ganz are normally $1800) and the invasiveness and precaution required (Swan-Ganz can only be used in ICU settings which increases the cost of use to patients).
The use of the Hickey system, on the other hand, is much cheaper (around $600), less risky, and doesn’t need to be administered in an ICU or CCU setting, nor does it need to be administered by cardiologists. The components include a two balloon catheter that is inserted into the esophagus and the attached monitoring system.
“Since the right atrium is in such close proximity to the esophagus, an esophageal catheter fits with a proper sensing apparatus that picks up mean atrial pressure, heartbeat, and other significant cardiovascular events,” said David LaVance, “Aside from the obvious benefit of eliminating the need for a surgical or highly invasive procedure, the Hickey system offers a number of other improvements over today’s standard for cardiac monitoring, including: performing phonocardiogram and monitoring audible heart sounds unaffected by surrounding noise, integrated ECG and blood pressure measurements, it is disposable and uses no metal components which would interfere with magnetic resonance imaging and its rapid insertion and positioning by non-physician personnel.”
LaVance noted that the Hickey system should garner 510(5) FDA approval by the fourth quarter with rollout and commercialization beginning in 2009. The accuracy of the data between the Swan-Ganz and the Hickey system is predicted to be statistically indifferent. That and the fact that it is much less invasive, risky and costly should help with an expedited 510(k) approval by the FDA.
In the meantime, the Company has entered into an agreement with Ethox to provide engineering and development support for the catheter component of the Hickey system in exchange for rights to manufacture the component following approval. The Hickey system development will also be partially funded through an incentive program by the New York State Office of Science Technology and Academic Research to The Research Foundation of the State University of New York and the Foundation’s company partner, Ethox. $750,000 was available under the program with Ethox matching that amount under the agreement.
The Company has also entered an agreement with Sparton Medical Systems who will provide the engineering and development for the hardware component while Applied Sciences Group has signed on for the development of software for the system. With the development team finalized, all eyes point towards FDA approval which is expected to be announced by the fourth quarter.
With approval, the market could greatly expand past what Edwards displayed in their Critical Care segment of $397 million for the year. According to a University of Buffalo research study, the Hickey system has tremendous market potential which will generate sales from the consumer catheter component and capital equipment. Its capabilities also make it well suited for other applications. Anesthesiologists might find it useful when monitoring patients undergoing treatment for aneurysms, trauma surgery or other heavy fluid loss surgeries requiring close monitoring of cardiac performance.
“The market for standard cardiac monitoring is more than 1 million procedures a year. It’s a figure that non-invasive technology could greatly expand because of its ability to be performed outside of intensive care units,” finished LaVance.
With an estimate of a $500 million overall market for non-invasive hemodynamic monitoring, Scivanta’s market cap of only $3.6 million could be severely undervalued with FDA approval and a market share grab of as little as 10%. Add in the population’s rising age, the propensity of heart disease, and a growth rate for the market between 15-30% and one can easily see this Company is one to follow. Investors would be wise to watch.
Visit 1800blogger to see all of our industry leading blogs.
Topics: Uncategorized | No Comments »
May 5, 2008
Market Scan for Small Cap Stocks on May 2, 2008
By admin
Submitted by Ducimus Plinius
Market Scan for small cap stocks
at the close of the markets on May 2, 2008
The table below identifies the stocks returned on my scan of the US markets for small capitalizations stocks likely to display the characteristics of stocks entering Phase II, as described by Stan Weinstein.
Ducimus Plinius is not a registered investment advisor. Please read the complete Small Cap Stocks Blog Disclaimer
Visit 1800blogger to see all of our industry leading blogs.
Topics: Uncategorized | No Comments »
May 4, 2008
Knobias Clip Report (05-02-2008)
By admin
Submitted By Knobias ClipReport
BPHX: Reports Strong Pipeline Following Record Pilot Deals & Mainframe Trend
Trading on BluePhoenix Solutions Ltd. (NASDAQ NM: BPHX) was up 11.042% following this morning’s earning’s call in which the company reported Q1 revenues of $24.04M, up 31.87% from last year and beating consensus by 1.74%. Q1 EPS was $.05. Adjusted Q1 EPS was $.21, up 50.00% from last year and matching consensus. Also driving the stock was news that analyst firm Collins Stewart had upgraded BPHX to a $20 target price, citing its growth and robust pipeline.
Though backlog continues to grow at an impressive rate, the company’s challenge remains on the service side, as headcount does not seem to be in proportion with growth due to hiring costs. However, organic growth is expected to increase from $80M last year to $100-$107M this year from TIS, a company it acquired to get mainframe access in India, which originally acted as a subcontractor to the company in a major deal it booked and shared revenues with.
During today’s conference call, the company reported a current backlog of $109M, which refers to a period of 12-18 months, up from last quarter’s $105M, and $85M from the quarter a year ago. Q1 was also a record high for pilots in the pipeline, as it did eight pilots for customers in Europe and in the U.S. that could add seven figures and up. Said CEO Arik Kilman, “We’re seeing a big move in this industry, especially with growth from potential partners, and we’ll announce some of them in the next three months.”
The company normally has many pilots in its pipeline, but what makes these new pilots different is the magnitude of the dollar value. Said Kilman, “We’re now we’re taking big pilots, and the reason is tied to the current macro environment where companies are trying to cut costs by moving away from their mainframe and central computer. New pilots to .Net will be able to perform as well as their original mainframe, so this trend leads to a much higher level of pilots than what we had last year or in Q1.”
As a result of a previous acquisition, the company has also expanded its partnership with Microsoft, as solution providers continue to move their applications to the .NET platform. Said Kilman, “We’re seeing lots of interest with solution providers who are interested in expanding their applications to .NET platform in order to sell more solutions to customers who have .NET, which is much larger target audiance. We’re on of the few company’s in the market succeeding in taking customers from their mainframes to .NeT, so the with expansions to .Net, coupled with increased market trends of companies downsizing mainframes to .NET, Microsoft has become significantly more interested in the prospects of working with us. This involves joint marketing at a different level, and more of their people are involved in sales cycles for technical assistance. Our confidentiality agreement, however, prevents us from getting too much into the details.”
Despite weakness in the financial sector, the company reports seeing no slowdown in services. This quarters financial breakdown shows 65% of total revenues came from financial institutions, and its exposure to U.S.-based investment services accounted for approximately 7% of revenue. By segment, Software was 5%, services 82%, and maintenance was 13%. Software represented a big decline from past quarters in total revenue, but the company stated that it has changed the way it will be recognized by focusing on higher margin business. “We cannot separate software and services, so definitions will change materially.”
Materially affected by 2 cents a share in Q1 was the company’s 2008 outlook, which it gave last August when the dollar was worth 4.3 sheckels. By December, it fell to 3.85, and currently holds at 3.45. Said Kilman, “The rate was higher during guidance, so unless the dollar strengthens, we’ll continue to see an impact on results throughout the year. Based on current Dollar/Shekel exchange rates, we expect revenues to grow and to be in the range of $101M-$107M, with profitability of $1.00-$1.05 earnings per share on a non-GAAP basis.”
Visit 1800blogger to see all of our industry leading blogs.
Topics: Uncategorized | No Comments »
May 2, 2008
Knobias Clip Report (5-1-2008)
By admin
Submitted By Knobias ClipReport
HOLX: Shares Plunge on Earnings Report
Thursday’s session saw oil dominate the headlines as Exxon Mobil (XOM) reported their earnings for the first quarter which displayed a revenue number of $116.85 billion. The number is almost astonishing. In comparison, Microsoft reported revenue of only $15 billion for their first quarter, and if they bought Yahoo!, the combined would only report revenue in the $16-17 billion area. That’s still a $100 billion shy of what Exxon raked in the past 3 months. Even if you add two Warren Buffets and throw in one in the Walton clan, just for good measure, and odds are, you’ll still come up short of Exxon sales for the next quarter.
But this is an apple to orange comparison. Technology and the net worth’s of the richest people on the face of the planet isn’t a fair litmus test. Even so, the idea that one company can make that much money is still astounding. And some of the media pundits calling for a redistribution of Exxon earnings are flirting with communist characteristics that are opposite of what this country was built upon.
But moving on, in the small cap space, another name reported earnings that had many take notice. Hologic Inc. (HOLX) is a diversified medical technologies company specializing in diagnostics, imaging systems and interventional devices dedicated to serving the healthcare needs of women.
The Company reported second quarter revenue totaling $431.0 million, a 138% increase when compared to revenues of $181.1 million in the second quarter of fiscal 2007. The increase was primarily attributable to the inclusion of approximately $189.2 million of revenues from the new product lines acquired in the merger with Cytyc Corporation on October 22, 2007. For the second quarter of fiscal 2008, Hologic reported net income of $56.0 million, or $0.22 per diluted share, compared with net income of $21.6 million, or $0.20 per diluted share, in the second quarter of fiscal 2007. Included in the second quarter of fiscal 2008 results were charges relating to the Cytyc merger of $25.1 million attributable to the amortization of intangibles and $0.8 million attributable to the increase in cost of revenues relating to the write-up of acquired inventory to fair market value.
Despite the growth, the numbers missed analyst expectations. Estimates called for earnings of $0.28 on $417.88 million in revenue. Following the 21% miss on the bottom line, shares plunged by almost the same amount. The stock ended at $23.75, off over 18.6% on the day.
The action caused multiple analysts to come to its defense. Jefferies noted that the sell off was overdone and reiterated its Buy rating. Citigroup noted that the weakness was a buying opportunity and they reiterated their Buy rating. Oppenheimer also came to the Company’s defense.
“This quarter marks our first full quarter since we completed our acquisition of Cytyc. We are pleased with our results and proud of our accomplishments to date — most notably, the alignment of our sales resources and our expanded product offerings,” said Jack Cumming, Chief Executive Officer in the earnings release. “We are beginning to see the sales synergies we had hoped for, especially in our Breast Health segment as the combined sales force has opened up a channel of opportunity for our interventional breast solutions business. Fiscal 2008 continues to look bright as we remain committed to our financial targets.”
With the healthcare industry growing at leaps and bounds because of an aging population, along with the Company’s synergistic efforts from the recent acquisition, the name could become one to follow over the coming months at these depressed prices. Investors would be wise to watch.
Topics: Uncategorized | No Comments »
May 1, 2008
Stock Picks and Trades Ideas For Thursday
By admin
Submitted by My Ambitions as a Trader and Investor
New Buy Candidates: BMI, GA, GFA (on a dip), GSI, LBAI, MPWR, NZ, OTEX, OWW, PDO, PWRD, QMM, TGX, UFI,
New Short Sale Candidates:
Add To: GLOB.OB, GNET, HDSN, SNT, TACT, VSCI, WEL, WHT
My Ambitions as a Trader and Investor is not a registered investment advisor. Please read the complete Small Cap Stocks Blog Disclaimer
Visit 1800blogger to see all of our industry leading blogs.
Topics: Uncategorized | No Comments »
